Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Suárez Álvarez, Beatriz ^a   Rodriguez, Ramón M ^a,b   Calvanese, Vincenzo ^c,d   Blanco Gelaz, Miguel A ^a   Suhr, Steve T ^b   Ortega, Francisco ^a,g   Otero, Jesus ^a   Cibelli, Jose B ^b,e   Moore, Harry ^f   Fraga, Mario F ^c,d   López Larrea, Carlos ^a,g  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^e Fundación Renal 'Íñigo Álvarez de Toledo' ^*

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g Section of Nephrology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BETA 2 MICROGLOBULIN; DNA; GAMMA INTERFERON; HLA DR ANTIGEN; HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR NKG2D; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRICHOSTATIN A; HISTOCOMPATIBILITY ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ALLOGRAFT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL DIFFERENTIATION; CELL SURFACE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; EMBRYO; EMBRYONAL CARCINOMA STEM CELL; EMBRYONIC STEM CELL; EPIGENETICS; GENE REPRESSION; GENETIC ANALYSIS; GENETIC REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOLECULAR RECOGNITION; PLURIPOTENT STEM CELL; PROTEIN TRANSPORT; SEQUENCE ANALYSIS; GENETIC EPIGENESIS; IMMUNITY; IMMUNOLOGY;

ACETYLATION; ANIMALS; CELL LINE; EPIGENESIS, GENETIC; GENE EXPRESSION; GERM CELLS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HISTONES; MALE; METHYLATION; MICE; OCTAMER TRANSCRIPTION FACTOR-3; PROMOTER REGIONS, GENETIC; SPERMATOGENESIS; STEM CELLS; ANTIGEN PRESENTATION; EMBRYONIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY; INDUCED PLURIPOTENT STEM CELLS;

EID: 77956337898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010192     Document Type: Article

References (52)

1. Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, et al. (2002) Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 99: 9864-9869.
2. Li L, Baroja ML, Majumdar A, Chadwick K, Rouleau A, et al. (2004) Human embryonic stem cells possess immune-privileged properties. Stem Cells 22: 448-456.
3. Drukker M, Katchman H, Katz G, Even-Tov Friedman S, Shezen E, et al. (2006) Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24: 221- 229.
4. Robertson NJ, Brook FA, Gardner RL, Cobbold P, Waldmann H, et al. (2007) Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A 104: 20920-20925.
5. Bonde S, Zavazava N (2006) Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 24: 2192-2201.
6. van den Elsen PJ, Gobin SJ, van der Stoep N, Datema G, Viëtor HE (2001) Transcriptional control of MHC genes in fetal trophoblast cells. J Reprod Immunol 52: 129-145.
7. Bubeni{dotless}́k J (2004) MHC class I down-regulation: tumour escape from immune surveillance? (Review). Int J Oncol 25: 487-491.
8. Seliger B (2008) Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 5: 361-367.
9. Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57: 1719-1726. Review.
10. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, et al. (2008) Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 26: 1275-1287.
11. Ishitani A, Sageshima N, Hatake K (2006) The involvement of HLA-E and -F in pregnancy. J Reprod Immunol 69: 101-113.
12. Hunt JS, Langat DL (2009) HLA-G: a human pregnancy-related immunomodulator. Curr Opin Pharmacol Jun 29, [Epub ahead of print] PubMed PMID: 19570712.
13. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, et al. (2009) HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 87(9 Suppl): S62-66.
14. Frenzel LP, Abdullah Z, Kriegeskorte AK, Dieterich R, Lange N, et al. (2008) Role of NKG2D-ligands and ICAM-1 in NK cell-mediated Lysis of Murine Embryonic Stem Cells and Embryonic Stem Cell-derived Cardiomyocytes. Stem Cells 27: 307-316.
15. Dressel R, Schindehü tte J, Kuhlmann T, Elsner L, Novota P, et al. (2008) The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS ONE 9 3(7): e2622.
16. López-Larrea C, Suárez-Alvarez B, López-Soto A, López-Vázquez A, Gonzalez S (2008) The NKG2D receptor: sensing stressed cells. Trends Mol Med 14: 179-189. Review.
17. González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López- Larrea C (2008) NKG2D ligands: key targets of the immune response. Trends Immunol 29: 397-403. Review.
18. Suárez-Alvarez B, López-Vázquez A, Baltar JM, Ortega F, López-Larrea C (2009) Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant 9: 251-257. Review.
19. Wright KL, Ting JP (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27: 405-412.
20. Zika E, Ting JP (2005) Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes. Curr Opin Immunol 17: 58-64. Review.
21. Koch CA, Geraldes P, Platt JL (2008) Immunosuppression by embryonic stem cells. Stem Cells 26: 89-98.
22. Wu DC, Boyd AS, Wood KJ (2008) Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 26: 1939-1950.
23. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, et al. (2007) Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21: 1345-1357.
24. Swijnenburg RJ, Tanaka M, Vogel H, Baker J, Kofidis T, et al. (2005) Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112(9 Suppl): I166-72.
25. Yachimovich-Cohen N, Even-Ram S, Shufaro Y, Rachmilewitz J, Reubinoff B (2010) Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism. J Immunol 184: 1300-8.
26. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
27. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
28. Suhr ST, Chang E, Rodriguez RM, Wang K, Ross PJ, et al. (2009) Telomere dynamics in human cells reprogrammed to pluripotency. PLoS ONE 4: e8124.
29. Grinnemo KH, Sylvén C, Hovatta O, Dellgren G, Corbascio M (2008) Immunogenicity of human embryonic stem cells. Cell Tissue Res 331: 67-78.
30. Yamanaka S (2009) A fresh look at iPS cells. Cell 137(1): 13-17.
31. Fehling HJ, Swat W, Laplace C, Kühn R, Rajewsky K, et al. (1994) MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265: 1234-1237.
32. Cabrera CM, Nieto A, Cortes JL, Montes RM, Catalina P, et al. (2007) The low rate of HLA class I molecules on the human embryonic stem cell line HS293 is associated with the APM components' expression level. Cell Biol Int 31: 1072-1078.
33. Bonde S, Zavazava N (2006) Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 24: 2192-201.
34. Dressel R, Nolte J, Elsner L, Novota P, Guan K, et al. (2010) Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J 24: 1-14.
35. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, et al. (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16: 800-13.
36. Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui JD (2009) Cutting edge: down-regulation of MHC class I-related chain A on tumour cells by IFNgamma- induced microRNA. J Immunol 182: 39-43.
37. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, et al. (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nature Immunol 9: 1065-1073.
38. Agúera-González S, Boutet P, Reyburn HT, Valés-Gómez M (2009) Brief residence at the plasma membrane of the MHC class I-related chain B is due to clethrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 182: 4800-4808.
39. Apps R, Gardner L, Traherne J, Male V, Moffett A (2008) Natural-killer cell ligands at the maternal-fetal interface: UL-16 bindingproteins, MHC class-I chain related molecules, HLA-F and CD48. Hum Reprod 23: 2535-2548.
40. Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, Antsiferova J, et al. (2006) Placenta-derived soluble MHC class I chain-related molecules downregulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 176: 3585-3592.
41. Clayton A, Mitchell JP, Court J, Linna S, Mason MD, et al. (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180: 7249-7258.
42. Hedlund M, Stenqvist AC, Nagaeva O, Kjellberg L, Wulff M, et al. (2009) Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 183: 340-31.
43. Chou SD, Khan AN, Magner WJ, Tomasi TB (2005) Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol 17: 1483-1494.
44. Menendez L, Walker LD, Matyunina LV, Totten KA, Benigno BB, et al. (2008) Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer 7: 43.
45. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532): 1074-1080.
46. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, et al. (2006) Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66: 3541-3549.
47. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, et al. (2007) Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1: 55-70.
48. CalvaneseV, Horrillo A, Hmadcha A, Suarez-Alvarez B, Fernandez AF, et al. (2008) Cancer genes hypermethylated in human embryonic stem cells. PLoS ONE 3: e3294.
49. Furue MK, Na J, Jackson JP, Okamoto T, Jones M, et al. (2008) Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci U S A 105: 13409-13414.
50. Draper JS, Moore HD, Ruban LN, Gokhale PJ, Andrews PW (2004) Culture and characterization of human embryonic stem cells. Stem Cells Dev 13: 325-336. Review.
51. Megiorni F, Mora B, Indovina P, Mazzilli MC (2005) Expression of neuronal markers during NTera2/cloneD1 differentiation by cell aggregation method. Neurosci Lett 373: 105-109.
52. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400.